Evaluations of ER, PR, and HER2 in tumor tissue are useful for predicting the potential outcome of postoperative adjuvant therapy of breast cancer; thus it was demonstrated that patients with triple-negative cancers had an obviously worse outcome than non-triple-negative cases during shorter follow-up periods of up to 3–5 years[1], [2], [3]. Here, ERBB2 is linked to breast carcinoma.